This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting. We do not share any your subscription information with third parties. It is used solely to send you notifications about site content occasionally.

Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

PYLO-X IS A REVOLUTIONARY SUPPLEMENT THAT CONTAINS PYLOPASS™ WHICH HAS BEEN SCIENTIFICALLY TESTED TO HELP MANAGE THE PRESENCE OF Helicobacter pylori (H. pylori) IN THE STOMACH.

PYLO-X works by binding to H. pylori and inactivating it without disturbing the normal microbial balance in the human organism. The addition of alpha-tocopherol, an antioxidant that is isolated and produced by biotechnological processes, helps heal the gastric lesions, which were demonstrated in the studies and will be described later. The dual-action of this supplement makes it unique, biotechnologically innovative, and important. In addition to its dual-action, the research showed there to be an absence of side effects. According to the 2019 antibiotic resistance threats report, “more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result.” (“Biggest Threats and Data.”)

Antibiotic-resistance is a growing concern for not only human lives, but also for the environment. By decreasing the amount of antibiotic usage, these numbers will decrease significantly. H. pylori therapy has failed in many cases due to non-compliance and growing antibiotic resistance. It has been proven that the eradication of H. pylori has a large impact on reducing the incidences of gastric cancer and can rapidly decrease active inflammation in the gastric mucosa; as well as prevent progression towards pre-cancerogenic lesions. It can also reverse gastric atrophy before the development of intestinal metaplasia. As a result, one can see that the earliest possible eradication of this infection will have a large, positive impact on human health. Unfortunately, due to the growing resistance to antimicrobial regimens, the effect of the treatment has dramatically declined, leading to a decrease in H. pylori eradication rate. Since H. pylori resistance to antibiotics remains high in most areas, the usage of an efficient regimen to eliminate H. pylori is required (Hu). By discovering a regimen that removes H. pylori from the human body without contributing to the antibiotic resistance epidemic, human health will increase due to the increased effectiveness.

Selecting appropriate treatments for H. pylori is difficult within each varying country. There is a growing request from the public for natural health supplements and treatments that lack side effects. Scientists have been inspired to search for a new treatment option. These factors have supported researchers in discovering, finding, and developing a unique supplement called PYLO-X.

Why is this supplement crucial and important when there are numerous other treatment options on the market? How does it differ from other products? How and why is it unique? Before these questions are answered, let us discuss Helicobacter pylori, and why it is a global problem that must be treated.

What is Helicobacter Pylori?

H. pylori is a microaerophilic, spiral-shaped, gram-negative bacteria. It has two to seven unipolar flagella, which will aid in mobility through viscous liquids. H. pylori was discovered in 1982 (Khatri). It was first discovered as Campylobacter pyloridis and then renamed as Helicobacter pylori. The infection is mostly acquired during childhood and the route of transmission is fecal-oral. This organism is known to cause severe illnesses like acute/chronic gastritis, gastric atrophy, gastric and duodenal peptic ulcers, gastric adenocarcinoma, and lymphoma. H. pylori has infected around 50 percent of the global population; however, there is a great inconsistency in the presence of this infection between developed and developing nations. The average occurrence in developed countries in those less than 40 years old is 20 percent, whereas developing countries have a prevalence rate of 80–90 percent (Mehling).

pylo-x H pylori

H. pylori can withstand the acidic environment of the stomach, by attachment to the gastric mucosa and colonizing inside the stomach. Infection by H. pylori in some cases may lead to an inflammatory response, as well as to an increase of secretion of gastric acid and formation of type-B gastritis. A dependent relationship between the load of H. pylori in the stomach and the severity of symptoms as well as the rate of onset of the disease is apparent. In the National Health and Nutrition Examination Survey III, a strong and positive correlation was depicted between H. pylori and gastric cancer mortality (Mehling). As H. pylori incidence and prevalence increased within the population, gastric cancer mortality rates increased, and vice versa. H. pylori can survive in the stomach by urease production, which is converted to ammonia that impairs the gastric mucosa and neutralizes acidic pH.

h pylori antibiotic resistance pylo-x

Symptoms and Diagnosis Tests
The most common symptoms of H. pylori include abdominal pain with burning sensations, increased pain on an empty stomach, and pain in the nighttime. Furthermore, unintentional weight loss is caused by poor appetite, bad taste in mouth, nausea, vomiting, bloating, and a feeling of fullness in the stomach, all caused by this organism. Often, patients complain about having bad breath, frequent burping, heartburn (gastric reflux), indigestion (dyspepsia), and belching. As a result of H. pylori infections, patients also have symptoms of anemia, dark stool (blood in the stool), irritable bowel syndrome, and hypochlorhydria.

The diagnosis of H. pylori infections includes a blood antibody test, Carbon-13 (13C) urea breath test, stool antigen test, scope test, and a CT scan.

Treatment of H. pylori and How it is a Global Issue
Due to its high resistance and survival rate, the H. pylori infection is difficult to treat. Therapeutic regimens work to completely eradicate H. pylori and include various combinations of:

  1. Proton pump inhibitors (known as PPI’s)
  2. Histamine (H2) blockers
  3. Bismuth subsalicylate
  4. Antibiotics (two to three antibiotics)

This combinational treatment has high risks of side effects and non-compliance.

Common side effects of this therapy include:

  1. Diarrhea and bloating
  2. Headache
  3. Nausea and vomiting
  4. Stomach pain and dry mouth
  5. Unusual or unpleasant taste in the mouth
  6. Constipation
  7. Fungal infection
  8. Changes in stool color
  9. Irritable bowel syndrome
  10. Osteoporosis (with chronic use of anti-acid medications)

The goal of complete eradication has been challenged by increasing the resistance and prevalence of infection; as well as a diversity of strains, usage of improper regimens, patient non-compliance, massive gastric bacterial loads, gene polymorphisms (IL-1B and CYP2C19) (Hu), and high risk of recurring infections causing the treatment to be more harmful than beneficial. In around 25–30 percent of H. pylori cases, antibiotic therapy fails, particularly because of the increasing resistance to antibiotics (Buckley). Antibiotic resistance is a large global problem and threat. It impacts all ages and can lead to prolonged hospital stays, higher medical costs, and increased mortality rates. The resistance of H. pylori is increasing worldwide, with primary and secondary resistance to clarithromycin, metronidazole, and levofloxacin reaching levels higher than 15 percent according to the new metaanalysis, published in Gastroenterology. This systematic review and meta-analysis had included 178 studies comparing 66,142 isolates from 65 countries. The most prevalent was resistance to metronidazole with the levels between 44 percent and 65 percent. The only exception to this total increase in prevalence was the resistance to primary clarithromycin in the Americas and South-East Asia regions, where it was 10 percent, and resistance to primary levofloxacin in the European region (11 percent) (Nelson).

Primary and secondary resistance to these medications is increasing, decreasing their effectivity. Multi-drugs are also at risk for an increase in resistance. “Resistance to both clarithromycin and metronidazole increased markedly in all WHO [World Health Organization] areas with available data, reaching 14 percent in the Eastern Mediterranean and Western Pacific regions, and 23 percent in the European region” (Karon). Antibiotic resistance is increasing for all types of medications, which will eventually hinder their functionality.

Investigators that researched the prevalence of antibiotic resistance of H. pylori in the World Health Organization regions noted that “...the implementation of local and national surveillance system networks and the development of new noninvasive techniques in clinical practice are urgently needed to improve treatment effectiveness and consequently limit the malignant and nonmalignant burden of HP [H. pylori] chronic infections” (Savoldi). New regimens that are non-invasive are sought out to improve the effectiveness and limit the virulent and non-virulent nature of H. pylori. Management of Helicobacter pylori through only eradication is a questionable option and is not always a reliable solution. PYLO-X is a biotechnologically innovative solution for H. pylori.

What is PYLO-X and how it differs from other current treatment options?
PYLO-X is a biotechnology innovative solution based on its unique ingredients and has no side effects. It contains Pylopass™ combined with alpha-tocopherol for faster gastric lesion healing.

Pylopass™ is a strain of Lactobacillus reuteri (DSM 17648) the new approach to control infection and possible clearing of H. pylori from the stomach. It can act as an H. pylori antagonist and has been selected from 700 types of lactobacillus species. Pylopass™ co-aggregates with H. pylori and reduces its bacterial load in the stomach.

Lactobacillus reuteri non-sporulating, gram-positive, facultative anaerobic bacteria. “L. reuteri was first isolated in 1962” (Mu). It is found that this organism can inhibit pathogenic bacteria and survive a wide variety of pH environments. L. reuteri, through competition with H. pylori, can inhibit the binding of H. pylori to glycolipid receptors in the stomach. As a result, L. reuteri reduces symptoms and the bacterial load of H. pylori. The usage of L. reuteri in the eradication of H. pylori as a supplementation causes the elimination of the pathogen without the common side effects found within antibiotic therapies (Mu). L. reuteri, contained in PYLO-X, serves to eliminate H. pylori efficiently and reduce side effects associated with typical treatment options. Pylopass™ contained in PYLO-X is acquired through two processes, both of which require the cells of L. reuteri to be inactivated so that the supplement is made stable enough for gastric conditions. These two processes consist of fermentation and spray drying from the cells of L. reuteri. The mechanism of action does not disturb the intestinal microbial balance through the fact that L. reuteri is no longer living (“Pylopass™ A New Approach”). Thus, Pylopass™ is a useful solution against H. pylori with its unique mode of action and positive effects. When L. reuteri DSMZ17648 (Pylopass™) co-aggregates with H. pylori a reduction in the 13C urea breath test can be observed. This was demonstrated in an independent study described later in the article. H. pylori levels were calculated by a 13C urea breath test method after 14 days of supplementation with a 6, 12, and 24 weeks follow-up afterward. In the test group, compared to the placebo group, a significant reduction of H. pylori was noted. These results confirm that Pylopass™ can effectively reduce the load of H. pylori (Mehling).

The reason for using L. reuteri is to decrease the therapeutic gap in asymptomatic infection. It gives patients a new option for lowering the risk of gastric ulcer or gastric carcinoma. L. reuteri prevents severe side effects and decreases the expenses of treatment. A study found that Pylopass™ has a preventive effect of secondary diseases and related symptoms due to H. pylori infection for at least six months (Mehling).

How Pylopass works on H. pylori
Through binding to and co-aggregation of H. pylori, Pylopass can mask the surface structures of the pathogen and cause its motility to become severely impeded. The aggregated pathogens can no longer adhere to the gastric mucosa and the Lactobacillus-Helicobacter complexes are cleared from the stomach (Buckley). An additional mode of action might be the competition for specific binding properties (Mehling).

pylopass kills h pylori

Another independent study aimed to find whether the strain L. reuteri DSM17648, which has shown to decrease H. pylori load, can furthermore improve gastrointestinal symptoms in patients with H. pylori-positive when it is used within 28 days of supplementation. The study concluded that “After 28 days of Pylopass supplementation the change in H. pylori load was measured by 13C urea breath test (13C-UBT) and the change in symptoms was determined by the Gastrointestinal Symptom Rating Scale (GSRS). Blood assessments were conducted to measure the physiological changes relevant in terms of safety” (Buckley).

Additionally, in the study conducted by Martin Buckley and his associates it was found that after 28 days of taking the supplement, the H. pylori load decreased in 62.5 percent of subjects and GSRS scores decreased in 66.7 percent of subjects. There were no side effects observed. The results show that L. reuteri DSM17648 can suppress H. pylori infection, and can improve the H. pylori-associated gastrointestinal symptoms. The decrease in H. pylori and symptoms, depicted by the data, indicate the supplements are functioning as intended.

The use of Pylopass has shown to be an alternative way of controlling H. pylori infection and avoiding side effects of current antibiotic treatment. The main goal of Buckley’s study was to investigate the potential effects of Pylopass supplementation over a longer period (four weeks instead of two weeks); as well as to look for the effects of L. reuteri DSM 17648 on gastric symptoms caused by H. pylori infection. The use of Pylopass shows promising results in achieving a reduction of bacterial levels, controlling inflammation, modulating an immune response, or inhibiting adherence of H. pylori to the gastric epithelium by reducing its motility. This could be promising as adjunctive therapy for the current H. pylori infection treatment to achieve higher eradication rates and improvement of H. pylori-associated gastrointestinal symptoms (Buckley).

From the study, we can conclude that Pylopass is a solution against H. pylori. Pylopass can reduce the load of the H. pylori in the stomach, improves symptoms associated with the H. pylori infection, and lacks side effects. In regards to safety, this supplement is an important innovation in the medical industry. Pylopass, an ingredient of PYLO-X, is more advantageous than probiotics. Due to the extreme physiological environment in the stomach, caused by bile acids, mechanical stress, acidic pH and gastric enzymes, the survival and metabolic activity of probiotics severely impaired. Compared to probiotics which require special conditions for storage and shipment, Pylopass is easy to ship and store due to its insensitivity to extreme temperatures and condition changes. Its shelf life is prolonged, which leads to a reduction in production costs (Mehling). Pylopass’s ability to remain active as a prepared, non-viable cell is indicative of its stability under the gastric environment. Its mechanism of action does not depend on its survival and does not disturb the intestinal microbial balance (“Pylopass A New Approach”).

PYLO-X is a unique supplement and not just because it contains Pylopass. Pylopass supplements have been on the market for quite some time already. PYLO-X is a unique mixture of Pylopass and alpha-tocopherol, an antioxidant, together.

By using different models, scientists show the relationship between oxidative stress and inflammation as well as diminished gastroprotective substances in the pathogenesis of gastric lesions. It was described that treatments with antioxidants like alpha-tocopherol can show advantageous effects in the development of gastric lesions. The effects of alpha-tocopherol may include a decrease in oxidative stress and inflammation as well as rehabilitating endogenous gastroprotective substances. This vitamin has shown the possibility of use as a therapy for gastric mucosal injuries. Alpha-tocopherol was shown to be protective against many pathological conditions like liver, cardiovascular and cerebrovascular diseases, as well as diabetes and cancer. The main role in gastric lesion formation play factors such as inflammation, endogenous gastroprotective substance, and oxidative stress. Some scientific models were used to discover the preventative effects of alpha-tocopherol on the gastric lesion formation. In gastric lesions induced by H. pylori, the use of alpha-tocopherol shows a decrease in oxidative stress. By improving gastric mucosal circulation alpha-tocopherol delays enzyme conversion and the formation of a gastric lesion. After alpha-tocopherol administration was found the reduction in the increase of myeloperoxidase activity, which was shown to be increased in H. pylori-induced gastric lesions and also attenuates gastric lesions and the formation of leucocyte-generated oxygen radicals. This all suggests that alpha-tocopherol reduces the severity of gastric lesions via the suppression of neutrophil infiltration. This vitamin is shown to minimize gastric acidity, comparable with that of proton pump inhibitors (PPI), drugs used to treat gastric ulcers, which decreases gastric acid secretion.

Yusof Kamisah and his associates concluded that vitamin E can be used as a protection against ulcerogenic agents due to its antioxidant and anti-inflammatory mechanisms. It is suggested to take this vitamin as a supplement to prevent the formation of the gastric lesions, which are caused by stress and aggressive factors, such as H. pylori. It can also be used as an adjunct to therapy in critically ill patients. An increase in the production of prostaglandins and high levels of glutathione in tissues bears an anti-ulcer activity of alpha-tocopherol.

The article written by Yusof Kamisah demonstrates the value of alpha-tocopherol as an antioxidant, as well as its contribution to healing damaged tissues. For example, within the gastric mucosa, alpha-tocopherol decreases inflammatory processes and increases the gastric barrier properties. Alpha-tocopherol’s protective effect can be used as a valuable asset in medical preparations. It can also be used as a prophylactic for gastric mucosal damage and as a treatment for gastritis and ulcers.

Another research was used to observe the consequence of palm vitamin E on the gastric lesion. It was also compared with ranitidine and showed that ranitidine’s impact on a gastric injury was not visible at one week, nor three weeks of treatment. In other words, four to six weeks are needed for ranitidine to minimize the ulcer index in humans. The rate of healing is depicted to be more effective in the presence of vitamin E. The magnitude of decrease in the mean ulcer index was visible in one week (78 percent) of treatment (Jaarin).

Based on the study, it was concluded that the addition of palm vitamin E can aid in the reduction and treatment of damage in the gastric mucosa. It has been revealed to be more potent in decreasing stress and inflammation when compared to PPI medications, which are currently being used as a treatment option for gastric mucosal injuries. This vitamin would be beneficial in the treatment of H. pylori.

Alpha-tocopherol boosts antioxidant defense, protects cell membranes, and enhances immune function. These valuable properties were utilized in creating PYLO-X. This supplement, a combination of Pylopass and alpha-tocopherol, can revolutionize and eventually, become a drug of choice in the treatment of H. pylori infection.

In conclusion
Through using PYLO-X as a clinically proven solution for H. pylori, treatment without the negative side effects of antibiotic therapy and chronic antacid therapy can be achieved. It has been scientifically proven that side effects are absent and it does not contribute to bacterial resistance. It is not impacted by antibiotics. It is affordable, quick, and long-lasting. It can treat and prevent the formation of stomach lesions. These results are apparent within two weeks of treatment as well. It is recommended to take it one capsule by mouth twice a day, morning and evening after the consumption of food. Depending on the severity of symptoms, one should take it for two to four weeks. PYLO-X is a unique and new innovation in the treatment of H. pylori infection.

References

Berry, Jennifer. "H. Pylori: Causes, Symptoms, and Stomach Ulcers." Edited by Daniel Murrell, Medical News Today, MediLexicon International, 1 Oct. 2017

"Biggest Threats and Data." Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, 14 Nov. 2019

"Common Side Effects of Prevpac (Lansoprazole, Amoxicillin and Clarithromycin) Drug Center." Edited by John P. Cunha, RxList, RxList, 25 June 2018

Hu, Yi, et al. "Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance." Frontiers in Cellular and Infection Microbiology, Frontiers Media S.A., 5 May 2017

Karon, Amy. "H. pylori Antibiotic Resistance Reaches 'Alarming Levels'." GI and Hepatology News, 18 Jan. 2019

Khatri, Minesh. "H. pylori Bacteria Infection: Symptoms, Diagnosis, Treatment, Prevention." WebMD, WebMD, 21 Dec. 2018

Mu, Qinghui, et al. "Role of Lactobacillus reuteri in Human Health and Diseases." Frontiers in Microbiology, Frontiers Media S.A., 19 Apr. 2018

Mehling, Heidrun, and Andreas Busjahn. "Non-Viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a New Approach to Helicobacter pylori Control in Humans." Nutrients, MDPI, 2 Aug. 2013

Nelson, Roxanne. "Resistance to Antibiotic Treatments for H Pylori Infection." Infectious Disease Advisor, 19 Aug. 2018

"Pylopass™ A New Approach in H Pylori Control." Elementa Ingredients.

Savoldi, Alessia, et al. "Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-Analysis in World Health Organization Regions." Gastroenterology, U.S. National Library of Medicine, Nov. 2018

"Helicobacter pylori: Epidemiology." Epidemiology, The Helicobacter Foundation

Buckley, Martin, et al. "The Effect of Lactobacillus reuteri Supplementation in Helicobacter pylori Infection: a Placebo-Controlled, Single-Blind Study." BMC Nutrition, BioMed Central, 7 Dec. 2018

Yusof Kamisah, Haji Mohd Saad Qodriyah, Kien Hui Chua & Mohd Fahami Nur Azlina (2014) Vitamin E: A potential therapy for gastric mucosal injury, Pharmaceutical Biology, 52:12, 1591-1597, DOI: 10.3109/13880209.2014.902082

Jaarin, Kamsiah, et al. "Comparative Effect of Palm Vitamin E and Ranitidine on the Healing of Ethanol-Induced Gastric Lesions in Rats." Edited by Masbah Omar, International Journal of Experimental Pathology, Blackwell Science Inc, Oct. 1999

Victoria Al Rabi, MD

Al Rabi Victoria Vyacheslavona, is a medical doctor specialized in internal medicine earned a degree in 1999, at Volgograd Medical University, Russia. She has always had a passion for research. During her student years at the university, she received letters of appreciation for participation in research from the Dept. of Therapy and from the Dept. of Toxicology and Military. In 2007, she received certification from ECFMG (Educational Commission for Foreign Medical Graduates). In addition to this, she received a certificate of completion for pre-clinical acculturation training from AmeriClerkships Medical Society. She has a certificate of completion “Protecting Human Research Participants” training course as well as certificates in HIPAA, BLS, ACLS, PALS, Blood Borne Pathogens and others. She is currently a member of the American Medical Association, a member of the American Medical Student Association, and a member of AmeriClerkships Medical Society. From 2012 until 2015, she was a Graduate Research Assistant at the Dept. of Emergency Medicine in Mt. Sinai Hospital, Chicago. She participated in studies like utilization violence prevention, diagnosis of unsuspected psychiatric illnesses in the emergency department (ED), boarding study, comparison usual ENA versus Canadian triage, compliance of medications by patients presenting in ED, and many others. Her passion for research and care for global problems are presented in the article “Pylo-x: The Innovative Solution For H.Pylori.”